Activity of azithromycin against Leishmania major in vitro and in vivo

American Journal of Tropical Medicine and Hygiene

Volumn 67, Issue 3, 2002, Pages 273-277

  Krolewiecki, Alejandro ^a   Leon, Shalom ^a   Scott, Phillip ^a   Abraham, David ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AZITHROMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; IMMUNE RESPONSE; LEISHMANIA MAJOR; LEISHMANIASIS; MACROPHAGE; MOUSE; NONHUMAN; PROMASTIGOTE;

ANIMALIA; LEISHMANIA MAJOR; PROTOZOA;

EID: 0036747490     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.67.273     Document Type: Article

References (36)

1. Berman JD, 1996. Treatment of New World cutaneous and mucosal leishmaniases. Clin Dermatol 14: 519-522.
2. Berman JD, 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years, Clin Infect Dis 24: 684-703.
3. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J, 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341: 1795-1800.
4. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH, 2002. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346: 891-895.
5. Gladue RP, Bright GM, Isaacson RE, Newborg MF, 1989. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33: 277-282.
6. Luke DR, Foulds G, Cohen SF, Levy B, 1996. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother 40: 2577-2581.
7. Lalak NJ, Morris DL, 1993. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 25: 370-374.
8. Foulds G, Shepard RM, Johnson RB, 1990. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25: 73-82.
9. Steigbigel NH, 1995. Macrolides and clindamycin. In Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infections Diseases. Churchill Livingstone, NY 334-336.
10. Schuster FL, Visvesvara GS, 1998. Efficacy of novel antimicrobials against clinical isolates of opportunistic amebas. J Eukaryot Microbiol 45: 612-618.
11. Hicks P, Zwiener RJ, Squires J, Savell V, 1996. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. J Pediatr 129: 297-300.
12. Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J, 1999. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 28: 74-81.
13. Sadiq ST, Glasgow KW, Drakeley CJ, Muller O, Greenwood BM, Mabey DC, Bailey RL, 1995. Effects of azithromycin on malariometric indices in The Gambia. Lancet 346: 881-882.
14. Andersen SL, Ager A, McGreevy P, Schuster BG, Wesche D, Kuschner R, Ohrt C, Ellis W, Rossan R, Berman J, 1995. Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo. Am J Trop Med Hyg 52: 159-161.
15. Puri SK, Singh N, 2000. Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys. Exp Parasitol 94: 8-14.
16. Beckers CJ, Roos DS, Donald RG, Luft BJ, Schwab JC, Cao Y, Joiner KA, 1995. Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii: implications for the target of macrolide antibiotics. J Clin Invest 95: 367-376.
17. Blais J, Garneau V, Chamberland S, 1993. Inhibition of Toxoplasma gondii protein synthesis by azithromycin. Antimicrob Agents Chemother 37: 1701-1703.
18. Blais J, Beauchamp D, Chamberland S, 1994. Azithromycin uptake and intracellular accumulation by Toxoplasma gondii-infected macrophages. J Antimicrob Chemother 34: 371-382.
19. Dumas JL, Chang R, Mermillod B, Piguet PF, Comte R, Pechere JC, 1994. Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. J Antimicrob Chemother 34: 111-118.
20. Schwab JC, Cao Y, Slowik MR, Joiner KA, 1994. Localization of azithromycin in Toxoplasma gondii-infected cells. J Antimicrob Chemother 38: 1620-1627.
21. Berman JD, Lee LS, 1984. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J Parasitol 70: 220-225.
22. Berman JD, Wyler DJ, 1980. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis 142: 83-86.
23. Berman JD, Dwyer DM, Wyler DJ, 1979. Multiplication of Leishmania in human macrophages in vitro. Infect Immun 26: 375-379.
24. Locksley RM, Scott P, 1991. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Immunol Today 12: A58-61.
25. Nashleanas M, Kanaly S, Scott P, 1998. Control of Leishmania major infection in mice lacking TNF receptors. J Immunol 160: 5506-5513.
26. Sacks DL, Perkins PV, 1984. Identification of an infective stage of Leishmania promastigotes. Science 223: 1417-1419.
27. Vieira LQ, Goldschmidt M, Nashleanas M, Pfeffer K, Mak T, Scott P, 1996. Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication. J Immunol 157: 827-835.
28. Tushinski RJ, Oliver IT, Guilbert LJ, Tynan PW, Warner JR, Stanley ER, 1982. Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell 28: 71-81.
29. Bermudez LE, Martinelli J, Petrofsky M, Kolonoski P, Young LS, 1994. Recombinant granulocyte-macrophage colonystimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis 169: 575-580.
30. Ouadrhiri Y, Scorneaux B, Sibille Y, Tulkens PM, 1999. Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. Antimicrob Agents Chemother 43: 1242-1251.
31. Xu G, Fujita J, Negayama K, Yuube K, Hojo S, Yamaji Y, Kawanishi K, Takahara J, 1996. Effect of macrolide antibiotics on macrophage functions. Microbiol Immunol 40: 473-479.
32. Mattock NM, Peters W, 1975. The experimental chemotherapy of leishmaniasis: II. the activity in tissue culture of some antiparasitic and antimicrobial compounds in clinical use. Ann Trop Med Parasitol 69: 359-371.
33. Neal RA, Matthews PJ, 1982. In vivo antileishmanial properties of pentavalent antimonial compounds. Trans R Soc Trop Med Hyg 76: 284.
34. Panosian CB, Barza M, Szoka F, Wyler DJ, 1984. Treatment of experimental cutaneous leishmaniasis with liposomeintercalated amphotericin B. Antimicrob Agents Chemother 25: 655-656.
35. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Iuvone T, D'Acquisto F, Di Rosa M, 2000. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 292: 156-163.
36. McDonald PJ, Pruul H, 1992. Macrolides and the immune system, Scand J Infect Dis Suppl 83: 34-40.